Vericel Corp

VCEL

Market cap $2.38B

BURLINGTON, Mass., July 16, 2026 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Company will report its second quarter 2026 financial results on Thursday, July 30, 2026. Vericel's management will host a conference call and webcast at 8:30 a.m. ET to discuss its financial results and business highlights.

10,000 Common Stock shares were sold for a transaction value of $402,000 at an average price of around $40.24 per share on June 18, 2026. The sale represented 38% of Halpin's direct Common Stock holdings, reducing his direct stake from 26,248 to 16,248 shares, though he also has options.

BURLINGTON, Mass., June 09, 2026 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Company will present at the 2026 Truist Securities MedTech Conference on Tuesday, June 16th, 2026.

Vericel NASDAQ: VCEL reported record first-quarter revenue and raised its full-year 2026 outlook, citing strong growth across its MACI cartilage repair franchise and Burn Care business, as well as expected NexoBrid procurement revenue from a new federal contract.

Vericel Corporation (VCEL) Q1 2026 Earnings Call Transcript

Vericel Corporation (VCEL) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of $0.15. This compares to a loss of $0.23 per share a year ago.

Total Revenue Increased 30% to $68.4 Million, with MACI Revenue Growth of 22% and Burn Care Revenue Growth of 91%

The average of price targets set by Wall Street analysts indicates a potential upside of 53.4% in Vericel (VCEL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

CAMBRIDGE, Mass., April 23, 2026 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Company will report its first-quarter 2026 financial results on Thursday, May 7, 2026. Vericel's management will host a conference call and webcast at 8:30 a.m. ET to discuss its financial results and business highlights.

CAMBRIDGE, Mass., April 02, 2026 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, has been awarded a ten-year contract valued at up to $197 million by the U.S. Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS), for the procurement of NexoBrid®, establishment and maintenance of a Vendor Managed Inventory (VMI) system, design and validation of a U.S based manufacturing facility, and the development of a next generation formulation and additional indication for NexoBrid.